Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer - PubMed (original) (raw)

Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer

Georgios Deftereos et al. PLoS One. 2011.

Abstract

Background: MicroRNA expression is severely disrupted in carcinogenesis, however limited evidence is available validating results from cell-line models in human clinical cancer specimens. MicroRNA-21 (mir-21) and microRNA-143 (mir-143) have previously been identified as significantly deregulated in a range of cancers including cervical cancer. Our goal was to investigate the expression patterns of several well-studied microRNA species in cervical samples and compare the results to cell line samples.

Methodology/principal findings: We measured the expression of mir-21 and mir-143 in 142 formalin-fixed, paraffin embedded (FFPE) cervical biopsy tissue blocks, collected from Dantec Oncology Clinic, Dakar, Senegal. MicroRNA expression analysis was performed using Taqman-based real-time PCR assays. Protein immunohistochemical staining was also performed to investigate target protein expression on 72 samples. We found that mir-21 expression increased with worsening clinical diagnosis but that mir-143 was not correlated with histology. These observations were in stark contrast to previous reports involving cervical cancer cell lines in which mir-143 was consistently down-regulated but mir-21 largely unaffected. We also identified, for the first time, that cytoplasmic expression of Programmed Cell Death Protein 4 PDCD4; a known target of mir-21) was significantly lower in women with invasive cervical carcinoma (ICC) in comparison to those with cervical intraepithelial neoplasia (2-3) or carcinoma in situ (CIN2-3/CIS), although there was no significant correlation between mir-21 and PDCD4 expression, despite previous studies identifying PDCD4 transcript as a known mir-21 target.

Conclusions: Whilst microRNA biomarkers have a number of promising features, more studies on expression levels in histologically defined clinical specimens are required to investigate clinical relevance of discovery-based studies. Mir-21 may be of some utility in predictive screening, given that we observed a significant correlation between mir-21 expression level and worsening histological diagnosis of cervical cancer.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1

Figure 1. Expression profiling data for mir-21 and mir-143 in cervical cancer cell lines and normal specimens.

Mir-143 was significantly down-regulated in all three cervical cancer cell lines, in agreement with previous studies. However, mir-21 was not significantly different to the normal specimens, even though in previous studies mir-21 has been observed to be significantly up-regulated in the same cell lines.

Figure 2

Figure 2. Expression profiling for (a) mir-21 and (b) mir-143 in 133 clinical samples stratified by histological diagnosis.

In contrast to the cell-line data presented in Figure 1, we observed a significant association between increased mir-21 expression an worsening histological diagnosis, however no significant associations for mir-143. There was a significant difference between all histological groups (ANOVA, _p_-value<0.0001) and furthermore, women with CIS/CIN2-3 had marginally higher mir-21 expression levels compared to those classified as Normal/HRHPV+ (pu = 0.0375 pa = 0.0563).

Figure 3

Figure 3. Micrographs showing PDCD4 staining of (a) Normal (HRHVP-) specimen and (b) ICC specimen.

Figure 4

Figure 4. Protein expression data measured by immunohistochemistry for cytoplasmic PDCD4 stratified by histological diagnosis.

Here we observed a significant association between cytoplasmic PDCD4 expression and sample histology.

Similar articles

Cited by

References

    1. Cowland JB, Hother C, Gronbaek K. MicroRNAs and cancer. APMIS. 2007;115:1090–1106. - PubMed
    1. Lynam-Lennon N, Maher SG, Reynolds JV. The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos Soc. 2009;84:55–71. - PubMed
    1. Reshmi G, Pillai MR. Beyond HPV: Oncomirs as new players in cervical cancer. Febs Letters. 2008;582:4113–4116. - PubMed
    1. Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: tools for cancer diagnostics. Gut. 2009;58:1546–1554. - PMC - PubMed
    1. Wang Y, Lee CGL. MicroRNA and cancer - focus on apoptosis. Journal of Cellular and Molecular Medicine. 2009;13:12–23. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources